Cambridge Investment Research Advisors, Inc. Bio N Tech Se Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Bio N Tech Se stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 4,577 shares of BNTX stock, worth $517,567. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,577
Previous 4,423
3.48%
Holding current value
$517,567
Previous $355,000
53.24%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding BNTX
# of Institutions
357Shares Held
38.3MCall Options Held
2.45MPut Options Held
2.29M-
Baillie Gifford & CO8.31MShares$939 Million0.75% of portfolio
-
Primecap Management CO Pasadena, CA4.52MShares$511 Million0.4% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.36MShares$493 Million2.05% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$214 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.81MShares$204 Million0.88% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $27.4B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...